3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
2
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cisplatin
118
Radiotherapy
114
Cyclophosphamide
93
Paclitaxel
85
Gemcitabine
74
Carboplatin
68
Filgrastim
60
Doxorubicin
57
Vincristine
56
Etoposide
56
Docetaxel
56
Fluorouracil
51
Cytarabine
41
Prednisone
40
Methotrexate
40
Leucovorin
39
Dexamethasone
37
Capecitabine
36
Irinotecan
35
Rituximab
29
Oxaliplatin
28
Granulocyte Colony-Stimulating Factor
27
Cetuximab
26
Bevacizumab
26
durvalumab
24
Temozolomide
24
Radiotherapy, Intensity-Modulated
24
Peripheral Blood Stem Cell Transplantation
24
Magnetic Resonance Spectroscopy
24
Surgical Procedures, Operative
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
NETWORK
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled